Document is current

Article History

Received: 19 August 2023

Revised: 20 December 2023

Accepted: 22 December 2023

First Online: 13 February 2024

Competing interests

: JM, NR, PP, PC, AF, DK, KH, AD: no interest to declare. TM: Honoraria from Roche, MSD/AZ, Novartis. AG: Honoraria from AZ, GSK, Roche, research funding from Roche, Pfizer, AZ. IC: Advisory board for AZ, Bayer, BMS, Eli Lilly, MSD, Roche. DC: Research funding from AZ, Eli Lilly, Roche. NS: Honoraria from Eli Lilly, Merck, MSD, Servier, GSK, Amgen; Research funding: AZ, BMS, Pfizer. SI: Advisory board and meeting support for Takeda, Kite, Beigene, Abbvie, BMS. SP: Honoraria/Consultancy from Amgen, AstraZeneca, Bayer, BeiGene, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, EQRx, GlaxoSmithKline, Guardant Health, Janssen, Lilly, Merck KGaA, MSD, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics, Takeda, Turning Point Therapeutics. Research funding: Amgen, AstraZeneca, Blueprint, BMS, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Guardant Health, Janssen, Lilly, MSD, Roche, Takeda, Seattle Genetics, Trizel, Turning Point Therapeutics. RL: funded by the Royal Marsden NIHR BRC, Royal Marsden Cancer Charity. RL’s institution receives compensation from NHSE for time spent in a secondment role for the lung health check programme and as a National Specialty Lead for the National Institute of Health and Care Research. He has received research funding from CRUK, Innovate UK (co-funded by GE Healthcare, Roche and Optellum), SBRI (including with Qure), RM Partners Cancer Alliance and NIHR (co-applicant in grants with Optellum). He has received honoraria from CRUK.

: The patient has consented for publication of this case report.